The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

被引：187

作者：

Leong, Darryl P. ^{[1
,2
]}

Caron, Francois ^{[1
]}

Hillis, Christopher ^{[3
,4
]}

Duan, Annie ^{[1
]}

Healey, Jeff S. ^{[1
,2
]}

Fraser, Graeme ^{[3
,4
]}

Siegal, Deborah ^{[2
]}

机构：

[1] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Dept Med, Hamilton, ON, Canada

[3] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

[4] Hamilton Hlth Sci, Hamilton, ON, Canada

来源：

BLOOD | 2016年 / 128卷 / 01期

关键词：

MANTLE-CELL LYMPHOMA; FOLLOW-UP; OFATUMUMAB; SAFETY;

D O I：

10.1182/blood-2016-05-712828

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：138 / 140

页数：3

共 25 条

[1] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[2] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[3] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Shaw, Yun ;

Bilotti, Elizabeth ;

Zhou, Cathy ;

James, Danelle F. ;

O'Brien, Susan .

BLOOD, 2015, 125 (16) :2497-2506

[4] Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study [J].

Chanan-Khan, Asher ;

Cramer, Paula ;

Demirkan, Fatih ;

Fraser, Graeme ;

Silva, Rodrigo Santucci ;

Grosicki, Sebastian ;

Pristupa, Aleksander ;

Janssens, Ann ;

Mayer, Jiri ;

Bartlett, Nancy L. ;

Dilhuydy, Marie-Sarah ;

Pylypenko, Halyna ;

Loscertales, Javier ;

Avigdor, Abraham ;

Rule, Simon ;

Villa, Diego ;

Samoilova, Olga ;

Panagiotidis, Panagiots ;

Goy, Andre ;

Mato, Anthony ;

Pavlovsky, Miguel A. ;

Karlsson, Claes ;

Mahler, Michelle ;

Salman, Mariya ;

Sun, Steven ;

Phelps, Charles ;

Balasubramanian, Sriram ;

Howes, Angela ;

Hallek, Michael ;

Assouline, S. ;

Bence-Bruckler, I. ;

Buckstein, R. ;

Fraser, G. ;

Larratt, L. ;

Minuk, L. ;

Villa, D. ;

Angevine, A. ;

Bartlett, N. ;

Bixby, D. ;

Caimi, P. ;

Chanan-Khan, A. ;

Craig, M. ;

Forero-Torres, A. ;

Ganguly, S. ;

Goy, A. ;

Heffner, L. ;

Hermann, R. ;

Lansigan, F. ;

Leis, J. ;

Letzer, J. .

LANCET ONCOLOGY, 2016, 17 (02) :200-211

[5] Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes [J].

Cheah, C. Y. ;

Chihara, D. ;

Romaguera, J. E. ;

Fowler, N. H. ;

Seymour, J. F. ;

Hagemeister, F. B. ;

Champlin, R. E. ;

Wang, M. L. .

ANNALS OF ONCOLOGY, 2015, 26 (06) :1175-1179

[6] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study [J].

Dreyling, Martin ;

Jurczak, Wojciech ;

Jerkeman, Mats ;

Silva, Rodrigo Santucci ;

Rusconi, Chiara ;

Trneny, Marek ;

Offner, Fritz ;

Caballero, Dolores ;

Joao, Cristina ;

Witzens-Harig, Mathias ;

Hess, Georg ;

Bence-Bruckler, Isabelle ;

Cho, Seok-Goo ;

Bothos, John ;

Goldberg, Jenna D. ;

Enny, Christopher ;

Traina, Shana ;

Balasubramanian, Sriram ;

Bandyopadhyay, Nibedita ;

Sun, Steven ;

Vermeulen, Jessica ;

Rizo, Aleksandra ;

Rule, Simon .

LANCET, 2016, 387 (10020) :770-778

[7] Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries [J].

Ekman, N ;

Lymboussaki, A ;

Vastrik, I ;

Sarvas, K ;

Kaipainen, A ;

Alitalo, K .

CIRCULATION, 1997, 96 (06) :1729-1732

[8]

Farooqui M., 2015, BLOOD, V126

[9] Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia [J].

Gustine, Joshua N. ;

Meid, Kirsten ;

Dubeau, Toni E. ;

Treon, Steven P. ;

Castillo, Jorge J. .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (06) :E312-E313

[10] Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program [J].

Hansson, Lotta ;

Winqvist, Maria ;

Asklid, Anna ;

Andersson, P-O ;

Karlsson, Karin ;

Karlsson, Claes ;

Lauri, Birgitta ;

Lundin, Jeanette ;

Mattsson, Mattias ;

Norin, Stefan ;

Sandstedt, Anna ;

Osterborg, Anders .

BLOOD, 2015, 126 (23)

← 1 2 3 →